06-30-2020, 04:01 PM
(06-29-2020, 09:07 AM)SHRacerX Wrote: Not the thread for it but there are different things being used beyond the antivirals that were mostly experimental at first. The treatments have improved tremendously as they are starting to realize that in many of the cases, blocking the complement system (a part of your innate immune system) aids in treatment tremendously.
Yeah, send me the information. I’d be greatly interested. How many complement blockers are currently FDA approved? Three? And none with an indication to treat infection?
Or are you including monoclonal antibodies as complement blockers? In which case only three are indicated for infections; RSV, anthrax, and C. diff.
And where are outpatient providers treating Covid 19 patients with convalescent mAbs? And in what numbers? Because a quick review of the literature indicates it’s use is also investigational as well.
Quote:If you really want more info, I can PM you details, but the treatments are much more effective at combating the effect of the virus than the early treatments. This is also very evident if you look at the reduction in morbidity and mortality.
Where are you getting this information about morbidity and mortality reduction because I can’t find that information with the CDC’s MMWR?
